Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation.

@article{Herman2003LosartanRT,
  title={Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation.},
  author={William H Herman and Shahnaz Shahinfar and George W. Carides and Erik J. Dasbach and William C. Gerth and Charles M. Alexander and John R. Cook and William F. Keane and Barry M. Brenner},
  journal={Diabetes care},
  year={2003},
  volume={26 3},
  pages={683-7}
}
OBJECTIVE To evaluate the within-trial effect of losartan and conventional antihypertensive therapy (CT) compared with placebo and CT on the economic cost associated with end-stage renal disease (ESRD). RESEARCH DESIGN AND METHODS The Reduction of End Points in Type 2 Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study was a multinational double-blind randomized placebo-controlled clinical trial designed to evaluate the renal protective effects of losartan on a background of… CONTINUE READING
23 Citations
11 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 11 references

Mortality and costs in the first year of dialysis: a comparison between hemodialysis (HD) and peritoneal dialysis (PD) (Abstract)

  • RA Wolfe, RA Hirth, +6 authors PJ Held
  • J Am Soc Nephrol 9:241A,
  • 1998
1 Excerpt

An Introduction to the Bootstrap

  • B Efron, RJ Tibshirani
  • 1993
1 Excerpt

Losartan reduces the costs associated with diabetic end - stage renal disease : the RENAAL study economic evaluation

  • BM Brenner, ME Cooper, D Seeuw

Similar Papers

Loading similar papers…